Conducted research to identify the frequency and the main causes of protein-energy malnutrition in children without parental care. Investigated the state of the vital systems (nervous, cardiovascular, digestive). Presented the efficiency of rehabilitation of children with malnutrition using probiotic Laminolakt “Chernichka”, confirmed the safety of its use.

The purpose of the review is to analyze the real benefits of the use of traditional probiotics and to highlight the issues of the possibility of creating and using new generation probiotics in the treatment of gastroenterological pathology. Questions of effectiveness of therapy with traditional probiotics of functional and organic diseases of the gastrointestinal tract in children and adults from the points of view of evidence-based medicine are analyzed, insufficient number of studies in children and frequent absence of significant differences in the effect of probiotics compared to placebo are emphasized. New generation probiotic candidates are described, which could become potential sources of new drugs for various diseases, including gastroenterological pathology. The main problems in the way of creation and introduction of new probiotics are outlined. Data on an alternative approach of probiotic therapy based on use to restore microbiocenosis of own bacteria, which are grown as pure genetically characterized cultures and can be used as probiotic products, are presented.

Objective. To evaluate the experience of using a probiotic strain of enterococcus in long-term nutritional support of premature infants.Characteristics of children and research methods. The children were selected in 2014–2015. The study included 11 premature babies of the first year of life, treated with antibiotics for a long time. Inclusion criteria: prematurity of any severity, signed informed consent from parents to conduct an outpatient rehabilitation program for children, including long-term nutritional support with a probiotic strain of enterococcus. Exclusion criteria: gross congenital malformations; hereditary metabolic diseases, severe forms of organic pathology of the central nervous system. Exclusion criteria: severe forms of somatic and infectious pathology, use of other probiotics. The probiotic strain of enterococcus – E. faecium L3 (No. RU. 77.99.26.009.Е.002272.02.11) in the liquid form (biomass grown on a dairy-free basis) with a titer of at least 108 CFU/ml was orally administered to children 1 ml 2 times a day while eating. The authors evaluated safety and clinical efficacy of long-term use of the probiotic strain of enterococcus.Results. The authors noted the effectiveness of long-term use of a probiotic strain of enterococcus as nutritional support for premature infants for adequate psychomotor and physical development. They revealed the disappearance of the manifestations of atopic dermatitis while taking a probiotic strain of enterococcus. In the course of the study, the safety of long-term intake of a probiotic strain of enterococcus was established as an integral part of the rehabilitation program for premature babies, who completed their nursing in a hospital.Conclusion. The continuation of studies to assess the clinical efficacy of long-term intake of probiotics in children of the first year of life who were born prematurely and received antibiotics for a long time can be considered very promising.

The aim of the study was to identify the features of the influence of autoprobiotic and probiotic E. faecium strains on clinical and laboratory parameters in children with functional gastroenterological pathology.Patients and methods. In the period 2020–2021. 35 children over 3 years of age with functional gastrointestinal disorders (FGID) were observed on an outpatient basis, who were prescribed an autoprobiotic or probiotic strain E. faecium for therapeutic purposes and recommended a diet.The study protocol provided for clinical and anamnestic screening, FGID diagnostics; analysis of coprograms and assessment of the composition of the intestinal microbiota in children before and after a course of probiotics. The study of intestinal microbiota was carried out by RT-PCR in feces using a set of primers “Colonoflor”. One patient was excluded from the study due to refusal to take the autoprobiotic.The rest of the patients formed two groups: group 1 (n = 16)—children who received the autoprobiotic strain and group 2 (n = 18)—children who received the conditionally “reference” strain E. faecium L3. Probiotics were used in the form of a liquid form (which is a starter culture based on soy protein isolates containing 109  CFU in 1 ml) at a dose of 25 ml 2 times a day for 10 days.The results of using probiotic strains were evaluated on the basis of data from a survey of parents about the state of children and the dynamics of clinical manifestations, as well as changes in the values of indicators of coprograms and the composition of the intestinal microbiota.Statistical processing of the results was carried out using Student’s t-test, Mann-Whitney U-test; Wilcoxon test. The results were considered reliable at a significance level of p <0.05.Results. Studies of the effect of prescribing E. faecium L3 strain and an autoprobiotic strain to children with FROP revealed a positive effect on the clinical symptoms of the disease (in 29.4% and 25%, respectively) in the absence of undesirable side effects. Analysis of the dynamics of coprograms revealed an equivalent positive dynamics in the form of improvement in most of the studied stool characteristics. The study of the composition of the intestinal microbiota in the observed children revealed a low level of Lactobacilli and Enterococcus before and after the administration of probiotics. After the course of the E. faecium L3 strain, a significant increase in the content of F. prausnitzii was noted. The use of an autoprobiotic strain contributed to a significant decrease in the frequency of isolation of conditionally pathogenic bacteria in large numbersConclusion. The course appointment of autoprobiotic and probiotic E. faecium strains in children with FGID has a positive effect on clinical symptoms, improvement of most coprogram indices and normalization of the intestinal microbiota composition.